Inside Drug Pricing - 02/12/2019

Former Antitrust Official: Rebate Ban May Lead To Higher Drug Prices

By John Wilkerson
February 6, 2019 at 11:45 AM
The proposed rule to eliminate drug rebates could take away plans’ power to lower drug prices, would not lower taxpayer spending on drugs, and the one problem it might alleviate, artificially high list prices, is likely already partially eased by mergers between insurers and pharmacy benefit managers, according to a former chief economist at the Justice Department’s antitrust agency. Yale University economics professor Fiona Scott-Morton said the better solution is to make drug companies pay insurers directly, instead of letting...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.